Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Portage Partners
United States
- Ownership
- Private
- Development stage
- Other
01
Overview
No approved products yet. Portfolio includes ten products at preclinical or early clinical stages. Notable assets include PORT‑8 and PORT‑9 adenosine antagonists in preclinical development for solid tumors/gastrointestinal cancers; iNKT engager program PORT‑3 in Phase I trials for advanced solid tumors.
- Therapeutic areas
- OncologyOphthalmology
- Modalities
- Small moleculeMonoclonal antibodyiNKT cell agonistAdenosine receptor antagonistAdjuvant therapy
- Industry
- Biotech
02
Partnerships
Not specifically listed; company states it discusses assets with potential big pharma partners during development process
Beyond the preview
Go deeper on Portage Partners.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Portage Partners.